ML162

Name: ML162
Brand: MedChemExpress
SKU: HY-100002
Rating: 5.0 (15 reviews)

Cat. No.: HY-100002 Purity: 99.52%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

ML162 is a covalent glutathione peroxidase 4 (GPX4) inhibitor. ML162 has a selective lethal effect on mutant RAS oncogene-expressing cell lines

For research use only. We do not sell to patients.

CAS No. : 1035072-16-2

Size	Stock	Quantity

Free Sample (0.1 - 0.2 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
1 g	In-stock	Estimated Time of Arrival: December 31
5 g	Get quote
10 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 15 publication(s) in Google Scholar

Other Forms of ML162:

ML162 (Standard) Get quote

15 Publications Citing Use of MCE ML162

Cell Proliferation/Viability Assay

: ML162 purchased from MedChemExpress. Usage Cited in: Nat Cancer. 2025 May;6(5):768-785. [Abstract]; The cell viability of mock or ZDHHC8-KO HT-1080 cells treated with DMSO, RSL3 (0.1 μM), ML162 (0.1 μM), IKE (1 μM) or IFNγ (20 ng/ml) plus AA (20 μM) together with or without Fer-1 (2 μM). For RSL3, ML162 and IKE, cells were treated for 24 h, and for IFNγ plus AA, cells were treated for 48 h.

: ML162 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Apr 5;16(1):254. [Abstract]; Cell viability of Huh7 or NCI-H23 cells treated with RSL3 (0.5 μM) or ML162 (0.5 μM), with or without ROT (10 μM) for 8 h, following pretreatment with NADH (1 mM) for 24 h.

: ML162 purchased from MedChemExpress. Usage Cited in: Cell Discov. 2024 Jun 4;10(1):60. [Abstract]; ML162 (0.075 µM; 72 h) alone or in combination with E/P significantly inhibits H526R cell growth.

: ML162 purchased from MedChemExpress. Usage Cited in: Mol Cell. 2023 Dec 7;83(23):4352-4369.e8. [Abstract]; Western blot analysis of GSTP1 protein levels in HT 1080 cells treated with ascending doses of ML162 (0.5-3 μM; 1-4 h) or for the different time durations (top). Quantitative results of three independent replicates (below).

: ML162 purchased from MedChemExpress. Usage Cited in: Am J Cancer Res. 2023 Feb 15;13(2):464-474.; Viability of CAL62 cells treated with different FINs (Erastin, 20 μM; ML210, 2 μM; ML162, 2 μM; all treated for 24 h).

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Glutathione Peroxidase Isoform Specific Products:

View All Isoforms

GPX1 GPX4

Biological Activity
Purity & Documentation
References
Customer Review

Description

ML162 is a covalent glutathione peroxidase 4 (GPX4) inhibitor. ML162 has a selective lethal effect on mutant RAS oncogene-expressing cell lines^[1]^[2]

IC₅₀ & Target

GPX4

Cellular Effect

Cell Line	Type	Value	Description	References
4T1	IC₅₀	2.52 μM Compound: 5; ML162	Cytotoxicity against mouse 4T1 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against mouse 4T1 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 34506134]
A549	IC₅₀	2.09 μM Compound: ML162	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 38295524]
ASPC1	IC₅₀	142 nM Compound: ML162	Induction of ferroptosis in human ASPC1 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Induction of ferroptosis in human ASPC1 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38265413]
BJ	IC₅₀	34 nM Compound: 1a	Cytotoxicity against human BJ cells expressing HRAS G12V mutant with alternative oncogenic constructs after 48 hrs by alamar blue assay Cytotoxicity against human BJ cells expressing HRAS G12V mutant with alternative oncogenic constructs after 48 hrs by alamar blue assay	[PMID: 22297109]
BT-549	IC₅₀	0.65 μM Compound: ML162	Antiproliferative activity against human BT-549 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human BT-549 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay	[PMID: 37452764]
HCT-116	IC₅₀	3.71 nM Compound: ML162	Induction of ferroptosis in human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Induction of ferroptosis in human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38265413]
HCT-116	IC₅₀	4.14 μM Compound: ML162	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 38295524]
HT-1080	IC₅₀	0.06 μM Compound: ML162	Antiproliferative activity against human HT-1080 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human HT-1080 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38838547]
HT-1080	IC₅₀	0.6 μM Compound: ML162	Cytotoxicity against human HT-1080 cells incubated for 48 hrs by CCK-8 assay Cytotoxicity against human HT-1080 cells incubated for 48 hrs by CCK-8 assay	[PMID: 38593589]
HT-1080	IC₅₀	0.66 μM Compound: 5; ML162	Cytotoxicity against human HT-1080 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HT-1080 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 34506134]
HT-1080	IC₅₀	0.76 μM Compound: ML162	Cytotoxicity against human HT-1080 cells incubated for 48 hrs by CCK-8 assay Cytotoxicity against human HT-1080 cells incubated for 48 hrs by CCK-8 assay	[PMID: 39230973]
HT-1080	IC₅₀	2 μM Compound: ML162	Cytotoxicity against human HT-1080 cells incubated for 48 hrs in presence of Fer-1 by CCK-8 assay Cytotoxicity against human HT-1080 cells incubated for 48 hrs in presence of Fer-1 by CCK-8 assay	[PMID: 39230973]
HT-1080	IC₅₀	7.31 μM Compound: 5; ML162	Cytotoxicity against human HT-1080 cells assessed as reduction in cell viability incubated for 48 hrs in presence of Fer-1 by MTT assay Cytotoxicity against human HT-1080 cells assessed as reduction in cell viability incubated for 48 hrs in presence of Fer-1 by MTT assay	[PMID: 34506134]
HepG2	IC₅₀	3.71 μM Compound: ML162	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 38295524]
MCF7	IC₅₀	10.1 μM Compound: 5; ML162	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 34506134]
MDA-MB-231	IC₅₀	0.16 μM Compound: ML162	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay	[PMID: 37452764]
MDA-MB-231	IC₅₀	2.27 μM Compound: ML162	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 38295524]
MDA-MB-231	IC₅₀	2.56 μM Compound: ML162	Induction of ferroptosis in human MDA-MB-231 cells assessed as cell viability incubated for 72 hrs in presence of ferroptosis inhibitor, ferrostatin-1 by MTT assay Induction of ferroptosis in human MDA-MB-231 cells assessed as cell viability incubated for 72 hrs in presence of ferroptosis inhibitor, ferrostatin-1 by MTT assay	[PMID: 37452764]
MDA-MB-468	IC₅₀	0.12 μM Compound: ML162	Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 37452764]
NCI-H522	IC₅₀	14 nM Compound: ML162	Induction of ferroptosis in human NCI-H522 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Induction of ferroptosis in human NCI-H522 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38265413]

In Vitro

ML162 (compound 1a) shows nanomolar potencies against two HRAS^G12V expressing cell lines, with IC₅₀ values of 25 nM and 578 nM for HRASG12V-expressing and wild-type BJ fibroblasts, respectively^[1].
ML162 (8 μM; 24 hours) treatment increases the expression of p62 and Nrf2 in chemoresistant HN3R and HN3-rslR cells, inactivates Keap1, and increases expression of the phospho-PERK-ATF4-SESN2 pathway^[2].
ML162 induces the head and neck cancer (HNC) cell death to varying degrees, with parental HN3 cells more sensitive and cisplatin-resistant (HN3R) and acquired RSL3-resistant (HN3-rslR) cells less sensitive^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[2]

Cell Line:	HN3R cells
Concentration:	8 μM
Incubation Time:	24 hours
Result:	Increased the expression of p62 and Nrf2 in chemoresistant HN3R and HN3-rslR cells.

Molecular Weight

477.40

Formula

C₂₃H₂₂Cl₂N₂O₃S

CAS No.

1035072-16-2

Appearance

Solid

Color

White to light yellow

SMILES

O=C(CCl)N(C(C1=CC=CS1)C(NCCC2=CC=CC=C2)=O)C3=CC=C(OC)C(Cl)=C3

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (209.47 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.0947 mL	10.4734 mL	20.9468 mL
5 mM	0.4189 mL	2.0947 mL	4.1894 mL
10 mM	0.2095 mL	1.0473 mL	2.0947 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (5.24 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.52%

Select Batch:

Data Sheet (277 KB) SDS (394 KB)

COA (251 KB) HNMR (272 KB) RP-HPLC (257 KB)

Handling Instructions (2659 KB)

References

[1]. Michel Weïwer, et al. Development of small-molecule probes that selectively kill cells induced to express mutant RAS. Bioorg Med Chem Lett. 2012 Feb 15;22(4):1822-6. [Content Brief]

[2]. Daiha Shin, et al. Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer. Free Radic Biol Med. 2018 Dec;129:454-462. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.0947 mL	10.4734 mL	20.9468 mL	52.3670 mL
	5 mM	0.4189 mL	2.0947 mL	4.1894 mL	10.4734 mL
	10 mM	0.2095 mL	1.0473 mL	2.0947 mL	5.2367 mL
	15 mM	0.1396 mL	0.6982 mL	1.3965 mL	3.4911 mL
	20 mM	0.1047 mL	0.5237 mL	1.0473 mL	2.6183 mL
	25 mM	0.0838 mL	0.4189 mL	0.8379 mL	2.0947 mL
	30 mM	0.0698 mL	0.3491 mL	0.6982 mL	1.7456 mL
	40 mM	0.0524 mL	0.2618 mL	0.5237 mL	1.3092 mL
	50 mM	0.0419 mL	0.2095 mL	0.4189 mL	1.0473 mL
	60 mM	0.0349 mL	0.1746 mL	0.3491 mL	0.8728 mL
	80 mM	0.0262 mL	0.1309 mL	0.2618 mL	0.6546 mL
	100 mM	0.0209 mL	0.1047 mL	0.2095 mL	0.5237 mL

ML162 Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

ML1621035072-16-2ML 162ML-162Glutathione PeroxidaseFerroptosisGPX4HRASanticancerNrf2p62ferroptosisInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

ML162

Customer Review

Other Forms of ML162:

ML162 Related Antibodies

15 Publications Citing Use of MCE ML162

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Glutathione Peroxidase Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

ML162 Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

ML162 Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report